Sertaconazole nitrate cream 2% for the treatment of tinea pedis

Cutis

Volumn 83, Issue 5, 2009, Pages 274-277

  Ribotsky, Bret M ^a  

^a Advanced Medical and Surgical Treatment of the Foot and Leg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; IMIDAZOLE DERIVATIVE; SERTACONAZOLE; THIOPHENE DERIVATIVE;

AGED; ARTICLE; CASE REPORT; FEMALE; HUMAN; MALE; OINTMENT; TINEA PEDIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS; ANTIFUNGAL AGENTS; FEMALE; HUMANS; IMIDAZOLES; MALE; OINTMENTS; THIOPHENES; TINEA PEDIS; TREATMENT OUTCOME;

EID: 68049085511     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. Spielfogel WD. Exploring the issues in treating tinea pedis. Podiatry Today. 2004;17(suppl 3A):10-18.
2. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50:748-752.
3. Walling HW, Sniezek PJ. Distribution of toenail dystrophy predicts histologic diagnosis of onychomycosis. J Am Acad Dermatol. 2007;56:945-948.
4. Blake N. Onychomycosis, routine callus care, diabetic foot examination in the outpatient setting and update on prescription foot orthoses. Curr Opin Orthop. 2005;16:50-53.
5. Zaias N, Rebell G. Chronic dermatophytosis caused by Trichophyton rubrum. J Am Acad Dermatol. 1996;35 (3, pt 2):S17-S20.
6. Baran R, Hay R, Haneke E, et al, eds. Onychomycosis: The Current Approach to Diagnosis and Therapy. London, England: Martin Dunitz Ltd; 1999.
7. Kyle AA, Dahl MV. Topical therapy for fungal infections. Am J Clin Dermatol. 2004;5:443-451.
8. Kosinski M, Joseph WS, Markinson B. Advances in the treatment of tinea pedis. Podiatry Management. June/July 2007:229-238.
9. Palacin A, Sacristán A, Ortiz JA. In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. Arzneimittelforschung. 1992;42:711-714.
10. Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycoses. a North American perspective. Drugs. 1998;55:645-674.
11. Carrillo-Muñoz AJ, Guglietta A, Palacín C, et al. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis. Chemotherapy. 2004;50:308-313.
12. Farré M, Ugena B, Badenas JM, et al. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung. 1992;42:752-754.
13. Liebel F, Lyte P, Garay M, et al. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res. 2006;298:191-199.
14. Sur R, Babad JM, Garay M, et al. Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway. J Invest Dermatol. 2008;128:336-344.
15. Savin R, Jorizzo J. The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis. Cutis. 2006;78:268-274.
16. Roujeau J-C, Sigurgeirsson B, Korting H-C, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004;209:301-307.